Cladribine post-mortem: NVS was one of the few large-cap stocks that was up yesterday—a day when the S&P 500 was down 1.6%. I wonder if someone at Merck KGaA leaked news of the FDA rejection of Cladribine, an action for which NVS is the biggest beneficiary.
Market Data 
Markets 
AI
